| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,058 |
6,800 |
$406K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,273 |
3,164 |
$302K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,672 |
3,657 |
$151K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,365 |
1,365 |
$110K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,040 |
1,040 |
$91K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,010 |
1,010 |
$83K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,498 |
1,475 |
$77K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
646 |
637 |
$53K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
668 |
662 |
$51K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
4,394 |
4,391 |
$40K |
| 90461 |
|
1,029 |
1,028 |
$38K |
| 92558 |
|
1,277 |
1,276 |
$31K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,622 |
2,619 |
$27K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,038 |
1,022 |
$25K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
765 |
761 |
$24K |
| 96127 |
|
2,009 |
2,007 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,361 |
1,339 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,027 |
548 |
$13K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
598 |
595 |
$10K |
| 99173 |
|
599 |
599 |
$9K |
| 99215 |
Prolong outpt/office vis |
89 |
86 |
$9K |
| 99177 |
|
544 |
544 |
$7K |
| 87081 |
|
1,013 |
994 |
$7K |
| 83655 |
|
598 |
597 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
887 |
886 |
$7K |
| 94760 |
|
2,210 |
2,127 |
$5K |
| 36416 |
|
391 |
391 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
41 |
41 |
$2K |
| 87634 |
|
15 |
15 |
$928.80 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
24 |
24 |
$705.38 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
24 |
24 |
$705.38 |
| 0072A |
|
12 |
12 |
$550.56 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
30 |
30 |
$457.80 |
| 92587 |
|
12 |
12 |
$202.68 |
| 81003 |
|
80 |
79 |
$169.50 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
28 |
28 |
$7.50 |